July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee BPC-157, KPV, TB-500, and MOTs-C bulk drug substances
This personalized assessment helps us create a safe and effective plan tailored just for you

COMPOSITION GHK-Cu: 50 mg BPC-157: 10 mg TB-500 (Thymosin Beta-4): 10 mg Appearance: Lyophilized powder in a sealed research vial RESEARCH FOCUS (NON-CLINICAL) Combined evaluation of copper peptide, BPC-157, and TB-500 in laboratory model systems Analytical assay development and validation for multi-peptide formulations Chromatographic method optimization for separation and impurity profiling Stability characterization of multi-component lyophilized peptide blends under laboratory storage conditions Identity and purity assessment using validated analytical methods DOCUMENTATION Lot-specific Certificate of Analysis (COA) Batch and lot traceability QR code access to product documentation Manufacturing quality documentation IMPORTANT NOTICE For research use only Not for human consumption Not intended for diagnostic, therapeutic, veterinary, or clinical use Not intended to diagnose, treat, cure, or prevent any disease QUALITY & MANUFACTURING Manufactured in the USA in an ISO 9001-based, cGMP-aligned facility Third-party tested with lot-specific Certificate of Analysis (COA) Lyophilized for laboratory stability and secure transit Tamper-evident seal with printed lot number and test date Each lot documented throughout production

The decision to prescribe a compounded medication is made by your licensed healthcare provider based on their independent medical judgment and your individual clinical needs